{
    "nct_id": "NCT03836352",
    "official_title": "A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.",
    "inclusion_criteria": "* Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy:\n\n  1. Epithelial ovarian, fallopian tube, or peritoneal cancer\n  2. Hepatocellular carcinoma\n  3. Non-small cell lung cancer\n  4. Urothelial cancer\n  5. Microsatellite instability high solid tumours, other than the above indications\n* Radiologic and/or biochemical evidence of disease progression\n* Completion of pre-treatment tumour biopsy\n* Must have measurable disease by RECIST v1.1\n* Ambulatory with an ECOG 0-1\n* Life expectancy ≥ 6 months\n* Meet protocol-specified laboratory requirements\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Chemotherapy or immunotherapy within treatment within 28 days of start of study treatment\n* Radiotherapy within treatment within 2 weeks of start of study treatment\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor where subject was discontinued from that treatment due to a Grade 3 or higher immune-related toxicity\n* For NSCLC subjects: Known EGFR mutations or ALK rearrangements\n* Prior receipt of survivin-based vaccine(s) and/or immunotherapies\n* Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer\n* Clinical ascites or pleural fluid that cannot be managed\n* Malignant bowel obstruction or recent history of bowel obstruction\n* For OvCa, subjects with any single lesion greater than 5 cm\n* Autoimmune disease requiring treatment within the last two years (except replacement therapy)\n* Recent history of thyroiditis\n* Any history of (non-infectious) pneumonitis that required steroid therapy or current pneumonitis\n* Presence of a serious acute or chronic infection\n* Active CNS metastases and/or carcinomatous meningitis\n* GI condition that might limit absorption of oral agents\n* Allogenic tissue/solid organ transplant\n* Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months\n* Ongoing treatment with steroid therapy or other immunosuppressive\n* Receipt of live attenuated vaccines\n* Acute or chronic skin and/or microvascular disorders\n* Edema or lymphedema in the lower limbs > grade 2\n* Severe hypersensitivity (≥ Grade 3) to pembrolizumab",
    "miscellaneous_criteria": "Key"
}